{"nctId":"NCT00620542","briefTitle":"CRESTOR Athero Imaging Head to Head IVUS Study","startDateStruct":{"date":"2008-01"},"conditions":["Coronary Atherosclerosis"],"count":2333,"armGroups":[{"label":"Rosuvastatin 20 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Rosuvastatin"]},{"label":"Atorvastatin 40 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Atorvastatin"]},{"label":"Rosuvastatin 40 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Rosuvastatin"]},{"label":"Atorvastatin 80 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Atorvastatin"]}],"interventions":[{"name":"Rosuvastatin","otherNames":["Crestor"]},{"name":"Atorvastatin","otherNames":["Lipitor"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical indication for coronary angiography\n* Angiographic evidence of Coronary Artery Disease (CAD), as defined by at least 1 lesion in a native coronary artery that has \\>20% reduction in lumen diameter by visual estimation\n* Left main coronary artery must have \\<=50% reduction in lumen diameter by visual estimation\n* LDL-C \\>100 mg/dL (2.6 mmol/L) for patients with no statin therapy in the past 4 weeks; LDL-C \\>80mg/dL (2.08mmol/L) for patients on therapy in the past 4 weeks\n\nExclusion Criteria:\n\n* Use of certain lipid-lowering medication for more than 3 months within the previous 12 months. Longer periods of treatment are not permitted because of the potential effects of such therapy on coronary atherosclerosis.\n* Patients who have symptoms consistent with moderate or greater severity of Congestive Heart Failure (CHF).\n* Clinically significant heart disease which, in the opinion of the Principal Investigator (or designee), is likely to require coronary bypass surgery, cardiac transplantation, surgical repair and/or replacement during the course of the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to End of Study (Week 104) in Percent Atheroma Volume (PAV)","description":"Change in PAV computed as PAV(Week 104)-PAV(baseline) where PAV is calculated as:\n\n\\[sum(EEMcsa-LUMENcsa)/sum EEMcsa\\]\\*100 where EEMcsa is the cross-sectional area of the external elastic membrane and LUMENcsa is the cross-sectional area of the lumen, as measured by intravascular ultrasound IVUS of a coronary artery in patients with CAD.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.22","spread":null},{"groupId":"OG001","value":"-0.99","spread":null}]}]}]},{"type":"SECONDARY","title":"Numbers of Patients Showing Regression in PAV","description":"Regression defined as a change from baseline in PAV \\< 0","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"356","spread":null},{"groupId":"OG001","value":"328","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End of Study (Week 104) in Total Atheroma Volume (TAV)","description":"Change in TAV, as measured by IVUS, computed as TAV(Week 104)-TAV(baseline) where TAV is the sum(EEMcsa-LUMENcsa)/n. n is the number of cross-sections measured. TAV for each patient is calculated as the average area of atheroma per cross-section multiplied by the median number of cross-sections measured for all patients in the analysis population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.39","spread":null},{"groupId":"OG001","value":"-4.42","spread":null}]}]}]},{"type":"SECONDARY","title":"Numbers of Patients Showing Regression in TAV","description":"Regression defined as a change from baseline in TAV \\< 0","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"371","spread":null},{"groupId":"OG001","value":"336","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Cholesterol Blood Level","description":"Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139.38","spread":"1.24"},{"groupId":"OG001","value":"144.05","spread":"1.23"}]}]}]},{"type":"SECONDARY","title":"LDL-C Blood Level","description":"Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.64","spread":"1.00"},{"groupId":"OG001","value":"70.18","spread":"0.99"}]}]}]},{"type":"SECONDARY","title":"HDL-C Blood Level","description":"Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.43","spread":"0.54"},{"groupId":"OG001","value":"48.64","spread":"0.53"}]}]}]},{"type":"SECONDARY","title":"Triglycerides Blood Level","description":"Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"132.50","spread":"2.44"},{"groupId":"OG001","value":"126.58","spread":"2.43"}]}]}]},{"type":"SECONDARY","title":"Non-HDL-C Blood Level","description":"Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.95","spread":"1.15"},{"groupId":"OG001","value":"95.41","spread":"1.14"}]}]}]},{"type":"SECONDARY","title":"LDL-C/HDL-C Blood Level","description":"Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.30","spread":"0.02"},{"groupId":"OG001","value":"1.50","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"Total Cholesterol/HDL-C Blood Level","description":"Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.88","spread":"0.03"},{"groupId":"OG001","value":"3.08","spread":"0.03"}]}]}]},{"type":"SECONDARY","title":"Non-HDL-C/HDL-C Blood Level","description":"Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.88","spread":"0.03"},{"groupId":"OG001","value":"2.08","spread":"0.03"}]}]}]},{"type":"SECONDARY","title":"Apolipoprotein B Blood Level","description":"Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.55","spread":"0.85"},{"groupId":"OG001","value":"75.12","spread":"0.85"}]}]}]},{"type":"SECONDARY","title":"Apolipoprotein A-1 Blood Level","description":"Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"146.81","spread":"1.03"},{"groupId":"OG001","value":"137.68","spread":"1.02"}]}]}]},{"type":"SECONDARY","title":"Apoliprotein B/Apolipoprotein A-1 Blood Level","description":"Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.51","spread":"0.01"},{"groupId":"OG001","value":"0.56","spread":"0.01"}]}]}]},{"type":"SECONDARY","title":"VLDL-C During the 104 Week Treatment Period","description":"Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.05","spread":"0.45"},{"groupId":"OG001","value":"25.03","spread":"0.44"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":21,"n":783},"commonTop":["MYALGIA","ANGINA PECTORIS","ARTHRALGIA","HYPERTENSION","FATIGUE"]}}}